OncoCyte (NASDAQ:OCX – Get Free Report) had its price objective boosted by equities researchers at Needham & Company LLC from $3.60 to $4.25 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target points to a potential upside of […]
Stephens reaffirmed their equal weight rating on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report released on Wednesday, Benzinga reports. They currently have a $4.00 price target on the stock. Several other research analysts have also commented on OCX. Benchmark reaffirmed a speculative buy rating and set a $5.00 price objective on […]
StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report released on Sunday. The firm issued a sell rating on the stock. OncoCyte Trading Up 0.3 % NASDAQ:OCX opened at $2.94 on Friday. OncoCyte has a one year low of $2.08 and a one year high of $7.20. The company has […]
Investment analysts at StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX – Get Free Report) in a note issued to investors on Sunday. The firm set a “sell” rating on the stock. OncoCyte Stock Performance OCX stock opened at $2.98 on Friday. OncoCyte has a one year low of $2.08 and a one year high […]
StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report published on Monday morning. The brokerage issued a sell rating on the stock. OncoCyte Price Performance NASDAQ OCX opened at $3.02 on Monday. The company’s 50 day moving average is $3.05 and its 200-day moving average is $3.10. OncoCyte has a […]